PDCD1 and non-small cell lung carcinoma: Finally, among 22 metastatic NSCLC patients receiving anti-PD-1/PD-L1 treatment, 97% of the cytokeratin (CK)+ patients had ≥1 PD-L1+ CTCs, which were isolated by vortex HT chip [15].